TEL, a member of the ETS family of transcription factors, is frequently involved in aberrations targeting chromosome 12, band 13 in human leukemia. One of these aberrations consists of a recurrent t(12;22), which is found in myeloproliferative disorders and is associated with a poor clinical prognosis. This translocation results in a chimeric gene that encodes a fusion protein, in which the N-terminus of TEL has been replaced by almost the entire sequence of MN 1, a nuclear protein of unknown function. This N-terminal substitution of TEL creates a protein containing MN 1-derived glutamine/proline-rich sequences linked to the ETS DNA-binding moiety of TEL, a configuration carrying the hallmarks of an activated transcription factor. Preliminary studies have shown that MN 1-TEL transforms NIH3T3 cells, which is in agreement with the hypothesis that the fusion protein plays a direct role in leukemogenesis. To understand how the fusion protein alters both MN1 and TEL function, we will first test the influence of functionally different domains of the fusion protein on DNA binding and transcription transactivation, and correlate these with transformation of NIH3T3 cells. Second, we will determine the transforming activity of the MN 1-TEL protein in vivo, using a transgenic mouse model. In addition, we will use overexpression of a dominant negative TEL protein to define the role of TEL in mouse lymphpoiesis. This animal model will also be analyzed to assess whether TEL may function as a tumor suppressor, as suggested by genetic evidence found in children with precursor B-cell acute leukemia. Finally, we will unravel the biologic pathway controlled by MN 1-TEL by identifying genes in NIH3T3 cells and myeloid cells whose altered expression in response to the fusion protein directly contributes to tumorigenesis. Results from these studies will provide a better insight into the role of MN I-TEL in tumorigenesis as well as the normal functions of TEL. Hopefully this basic research will lead to the development of novel approaches for treatment of t( I 2;22) myeloid diseases, thereby improving their poor prognosis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA072996-03
Application #
2895802
Study Section
Pathology B Study Section (PTHB)
Program Officer
Shen, Grace L
Project Start
1997-07-01
Project End
2001-04-30
Budget Start
1999-05-01
Budget End
2000-04-30
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Numata, Masashi; Yener, Mehmet Deniz; Ekmekçi, Sema S?rma et al. (2015) High MN1 expression increases the in vitro clonogenic activity of primary mouse B-cells. Leuk Res 39:906-12
Kandilci, Ayten; Grosveld, Gerard C (2009) Reintroduction of CEBPA in MN1-overexpressing hematopoietic cells prevents their hyperproliferation and restores myeloid differentiation. Blood 114:1596-606
Grosveld, Gerard C (2009) Gamma-secretase inhibitors: Notch so bad. Nat Med 15:20-1
Grosveld, Gerard C (2007) MN1, a novel player in human AML. Blood Cells Mol Dis 39:336-9
van Wely, Karel H M; Molijn, Anco C; Buijs, Arjan et al. (2003) The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription. Oncogene 22:699-709
Potter, M D; Buijs, A; Kreider, B et al. (2000) Identification and characterization of a new human ETS-family transcription factor, TEL2, that is expressed in hematopoietic tissues and can associate with TEL1/ETV6. Blood 95:3341-8
Van Rompaey, L; Dou, W; Buijs, A et al. (1999) Tel, a frequent target of leukemic translocations, induces cellular aggregation and influences expression of extracellular matrix components. Neoplasia 1:526-36